The Food and Drug Administration (FDA) has approved new single-dose prefilled syringes for Emerphed® (ephedrine sulfate injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.
The Emerphed prefilled syringes are ready-to-use and require no assembly. The new formulation is available immediately as 25mg/5mL and 50mg/10mL single-dose prefilled syringes in 10-count cartons.
“We are pleased to announce the addition of our latest Emerphed® product to our suite of existing FDA-approved, ready-to-use ephedrine sulfate products,” said CEO and President, Usman Ahmed. “These patented products showcase Nexus’ ability to provide innovative therapies that address clinicians’ concerns about delivering efficient and safe medications. With Emerphed®, we look forward to transforming how patients are treated, while continuing to offer the quality they’ve come to expect.”
Ephedrine sulfate works by directly acting as an alpha- and beta-adrenergic agonist and indirectly causing the release of norepinephrine. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Ephedrine sulfate stimulates heart rate and cardiac output and variably increases peripheral resistance, resulting in increased blood pressure.
Emerphed is also available as 50mg/10mL ready-to-use, single-dose vials in 10-count cartons.
- Nexus Pharmaceuticals, Inc. receives FDA approval for Emerphed® (ephedrine sulfate injection) pre-filled syringe. News release. Nexus Pharmaceuticals. Accessed March 1, 2023. https://www.businesswire.com/news/home/20230301005543/en/Nexus-Pharmaceuticals-Inc.-Receives-FDA-Approval-for-EMERPHED%C2%AE-ephedrine-sulfate-injection-Pre-Filled-Syringe.
- Emerphed. Package insert. Nexus Pharmaceuticals; 2023. Accessed March 1, 2023. https://21078818.fs1.hubspotusercontent-na1.net/hubfs/21078818/EMERPHEDPFSPI.pdf.